ArticleInternational journal of colorectal disease2026
Consequences of omitting additional treatment after local excision of high-risk early rectal cancer: a national cohort.
Article in International journal of colorectal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate oncological outcomes in patients with high-risk early rectal cancer undergoing local excision, comparing those who received guideline-recommended additional treatment to those who did not, either due to comorbidities or personal preference.
methodNational data on patients treated by transanal endoscopic microsurgery (TEM) or transanal minimally invasive surgery (TAMIS) for early rectal cancer without prior chemoradiotherapy between 2010 and 2020 were analyzed retrospectively. Patients were classified into low-risk (pT1 without risk factors for lymph node involvement) and high-risk (pT1 with risk factors and all pT2). High-risk patients receiving additional treatment (mainly completion TME, or less frequently adjuvant chemoradiotherapy for high-risk pT1) were compared to those without further treatment. Endpoints were 5-year relative survival, disease-free survival, overall survival, local recurrence, and distant recurrence.
resultsAmong 298 patients, 70 (23.5%) were low-risk pT1, 153 (51.3%) were high-risk pT1, and 75 (25.2%) were pT2. Additional treatment was omitted in 93 (60.8%) of high-risk pT1 and 39 (52.2%) of pT2 cases. Compared to patients following guidelines, those not receiving additional treatment had lower 5-year disease-free survival of 53.3% vs. 80.9% (p = 0.008) and higher 5-year local recurrence rates of 22.0% vs. 7.3% (p = 0.008). Five-year overall survival was 63.9% vs. 90.6% (p = 0.013), and relative survival 81.9% vs. 97.7% (p = 0.157).
conclusionOmitting indicated additional treatment following TEM or TAMIS for high-risk early rectal cancer is associated with a substantially higher local recurrence rate and loss of long-term disease-free survival and overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.